European Medicines Agency recently started monitoring reports of myocarditis followed by CoViD-19 vaccines and requested marketing authorisation holders to provide detailed data including age and gender analysis for the agency’s review and consideration. About a month ago, Israel reported several cases of myocarditis, many cases in young subjects (30 years or less) were, in particular, a concern and triggered further investigation. Recently, similar cases were also reported in Connecticut in adolescents and young adults, and some US troops also developed myocarditis post-vaccination that triggered a Pentagon investigation. The myocarditis (inflammation of the heart muscle) has been reported so far with the mRNA CoViD vaccines (Pfizer and Moderna), however, our analysis of the UK’s adverse events reports revealed a strong signal for myocarditis and related cardiac conditions for both viral vector CoViD vaccines (AstraZeneca) and mRNA vaccines (Pfizer/Moderna), therefore, should be thoroughly investigated by the regulatory agencies for its broader cardiovascular safety implication. A comprehensive safety review is imperative to reassure that the risks associated with genetic vaccines in the young population do not outweigh the perceived benefits. Vaccines are one of the great discoveries in medicine that has improved life expectancy dramatically. Nevertheless, genetic vaccines are new, and their long-term safety evaluation is invaluable for public safety.
|Number of pages||1|
|Publication status||E-pub ahead of print - 14 Jun 2021|